Technical Perspectives on TrovaGene, Accelerate Diagnostics, NeoGenomics, and Exact Sciences

Thursday, December 14, 2017 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, December 14, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely

information, WallStEquities.com has issued free tailored Stock Review on TROV, AXDX, NEO, and EXAS which is a click away at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com monitors TrovaGene Inc. (NASDAQ:
TROV), Accelerate Diagnostics, Inc. (NASDAQ: AXDX), NeoGenomics Inc. (NASDAQ: NEO), and Exact Sciences Corp. (NASDAQ: EXAS). Medical Laboratories and Research companies focus on performing various tests on patients that give them information on patients' health. These firms, as a whole, tend to offer higher dividend yields than the wider Healthcare sector. Wall St. Equities explores the latest technical developments on today's equity selection at:

www.wallstequities.com/registration

TrovaGene 

Shares in San Diego, California headquartered TrovaGene Inc. saw a decline of 6.06%, ending Wednesday's trading session at $0.46. The stock recorded a trading volume of 472,002 shares. The Company's shares are trading 33.22% below their 50-day moving average. Moreover, shares of TrovaGene, which focuses on the development and commercialization of proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research, and medical testing in various clinical disciplines in the US, have a Relative Strength Index (RSI) of 25.50.

On December 12th, 2017, TrovaGene announced that its proprietary NextCollect™ urine collection and DNA preservation kit is now available, for research use only, to clinical research laboratories and pharmaceutical customers. NextCollect is being offered to both existing contracted clients and to new customers through an online ordering web distribution portal. It enables high-volume, non-invasive urine sample collection and isolation of DNA, and has the potential to expand the utility of nucleic acid testing from urine, including oncology, virology, and infectious disease. Complimentary subscription to our free research report on TROV at:

www.wallstequities.com/registration/?symbol=TROV

Accelerate Diagnostics 

Tucson, Arizona headquartered Accelerate Diagnostics, Inc.'s stock plummeted 4.83%, closing the day at $28.55 with a total trading volume of 456,054 shares. The Company's shares have advanced 49.09% in the past month, 22.27% in the previous three months, and 37.59% since the start of this year. The stock is trading 26.97% and 15.40% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Accelerate Diagnostics, which provides solutions for the diagnosis of serious infections in the US, have an RSI of 61.86.

On November 16th, 2017, Accelerate Diagnostics announced the election of Charles Watts, M.D. to the Company's Board of Directors, effective November 14th, 2017. Dr. Watts has held a number of clinical and administrative leadership positions at two renowned academic medical centers: Northwestern (Feinberg School of Medicine, Northwestern Memorial Hospital) and the University of Michigan.

On December 13th, 2017, research firm BTIG Research downgraded the Company's stock rating from 'Buy' to 'Neutral'. Access the free research report on AXDX now by signing up at:

www.wallstequities.com/registration/?symbol=AXDX

NeoGenomics 

On Wednesday, shares in Fort Myers, Florida headquartered NeoGenomics Inc. recorded a trading volume of 259,416 shares. The stock ended the day 0.98% lower at $9.11. The Company's shares have advanced 6.05% in the past month and 6.30% on an YTD basis. The stock is trading above its 200-day moving average by 3.11%. Furthermore, shares of NeoGenomics, which together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the US, have an RSI of 48.64.

On December 05th, 2017, NeoGenomics has signed an agreement with Thermo Fisher Scientific to join the Next-Generation Sequencing Companion Dx Center of Excellence Program. NeoGenomics is one of the first laboratories to offer the newly FDA-approved Oncomine Dx Target Test for Non-Small Cell Lung Cancer. This methodology allows rapid analysis of samples compared to previously approved testing approaches. Are you already registered with Wall St. Equities? Do so now for free, and get the report on NEO at:

www.wallstequities.com/registration/?symbol=NEO

Exact Sciences 

Madison, Wisconsin headquartered Exact Sciences Corp.'s stock rose 3.31%, finishing yesterday's session at $51.88 with a total trading volume of 1.68 million shares. The Company's shares have surged 24.56% in the previous three months and 288.32% on an YTD basis. The stock is trading above its 200-day moving average by 34.59%. Additionally, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, have an RSI of 40.93. Aspiring Member, please take a moment to register below for your free research report on EXAS at:

www.wallstequities.com/registration/?symbol=EXAS

--

Wall St. Equities: 

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@wallstequities.com Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store